ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
Détails
ID Serval
serval:BIB_E494E62E3073
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
Périodique
Nature
ISSN
1476-4687 (Electronic)
ISSN-L
0028-0836
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
464
Numéro
7287
Pages
405-408
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.
Mots-clé
Alleles, Anemia, Hemolytic/chemically induced, Anemia, Hemolytic/complications, Antiviral Agents, Chromosomes, Human, Pair 20, Continental Population Groups/genetics, Europe/ethnology, Genetic Variation/genetics, Genome-Wide Association Study, Hemoglobins/deficiency, Hemoglobins/metabolism, Hepatitis C, Chronic/complications, Hepatitis C, Chronic/drug therapy, Humans, Polymorphism, Single Nucleotide/genetics, Pyrophosphatases/deficiency, Pyrophosphatases/genetics, Ribavirin/therapeutic use, United States
Pubmed
Web of science
Création de la notice
01/03/2012 16:14
Dernière modification de la notice
20/08/2019 17:08